3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
18
Gastrointestinal
17
Gynecologic
11
Genitourinary
8
Breast
6
Dermatologic
3
Head & Neck
1
Endocrine
1
CNS
1
Conditions
Brain Neoplasms
290
Glioblastoma
260
Glioma
202
Neuroblastoma
88
Neoplasms
62
Astrocytoma
56
Central Nervous System Neoplasms
54
Medulloblastoma
48
Breast Neoplasms
44
Melanoma
40
Sarcoma
39
Meningioma
39
Neurofibromatosis 1
38
Carcinoma, Non-Small-Cell Lung
38
Lung Neoplasms
37
Ependymoma
36
Osteosarcoma
31
Rhabdomyosarcoma
30
Neoplasm Metastasis
28
Sarcoma, Ewing
27
Rhabdoid Tumor
27
Diffuse Intrinsic Pontine Glioma
27
Recurrence
26
Oligodendroglioma
23
Gliosarcoma
22
Wilms Tumor
21
Pancreatic Neoplasms
21
Pheochromocytoma
20
Hepatoblastoma
20
Neurofibroma, Plexiform
19
Interventions
pembrolizumab
1
lenvatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
CNS
×
90 days
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts